| 日付 | 受信時刻 | ニュースソース | 見出し | コード | 企業名 |
| 2024/05/29 | 05 : 16 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 2024/05/25 | 05 : 18 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 2024/05/25 | 05 : 14 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 2024/05/25 | 05 : 13 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 2024/05/23 | 22 : 00 | GlobeNewswire Inc. | Esperion to Participate in Upcoming June Investor Conferences | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 2024/05/22 | 21 : 00 | GlobeNewswire Inc. | First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 2024/05/21 | 05 : 14 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 2024/05/20 | 19 : 00 | GlobeNewswire Inc. | Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 2024/05/18 | 04 : 08 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 2024/05/14 | 21 : 00 | GlobeNewswire Inc. | Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET® | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 2024/05/11 | 05 : 00 | GlobeNewswire Inc. | Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 2024/05/09 | 05 : 31 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 2024/05/07 | 21 : 50 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 2024/05/07 | 20 : 29 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 2024/05/07 | 19 : 00 | GlobeNewswire Inc. | Esperion Reports First Quarter 2024 Financial Results | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 2024/04/29 | 21 : 00 | GlobeNewswire Inc. | Esperion to Participate in Upcoming May Investor Conferences | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 2024/04/23 | 21 : 00 | GlobeNewswire Inc. | Esperion to Report First Quarter 2024 Financial Results on May 7 | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 2024/04/08 | 03 : 45 | GlobeNewswire Inc. | Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 2024/04/01 | 21 : 00 | GlobeNewswire Inc. | Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024 | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 2024/03/26 | 21 : 00 | GlobeNewswire Inc. | Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 2024/03/26 | 05 : 00 | GlobeNewswire Inc. | Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24 | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 2024/03/23 | 07 : 26 | Business Wire | U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 2024/03/23 | 04 : 10 | GlobeNewswire Inc. | U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 2024/03/23 | 00 : 04 | GlobeNewswire Inc. | CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 2024/02/27 | 23 : 19 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 2024/02/27 | 21 : 23 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 2024/02/27 | 20 : 00 | GlobeNewswire Inc. | Esperion Reports Fourth Quarter and Full Year 2023 Financial Results | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 2024/02/17 | 06 : 30 | GlobeNewswire Inc. | Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 2024/02/15 | 04 : 14 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:ESPR | Esperion Therapeutics Inc |
| 2024/02/15 | 00 : 50 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:ESPR | Esperion Therapeutics Inc |